Ruti Aga: Two Years for the Injection, Four for the Paperwork
**मुख्य उत्तर**: रूटी अगा को छह साल का प्रतिबंध एथलेटिक्स इंटीग्रिटी यूनिट ने दिया — दो साल मिथाइलप्रेडनिसोलोन की उपस्थिति के लिए और चार साल फर्ज़ी पर्चे के ज़रिये छेड़छाड़ के लिए। प्रतिबंध दस सितंबर से प्रभावी है, जो उनके प्रोविज़नल सस्पेंशन की तारीख़ भी है। **मुख्य तथ्य**: - मिथाइलप्रेडनिसोलोन ग्लुकोकोर्टिकॉइड (WADA वर्ग S9) है, एनाबॉलिक स्टेरॉयड नहीं; यह केवल प्रतियोगिता के भीतर प्रतिबंधित है। - पर्चा ऐसे क्लिनिक का था जो अस्तित्व में नहीं था; लिखने वाला परिवार का सदस्य बिना मेडिकल रजिस्ट्रेशन था। - मार्च में चीन की हाफ मैराथन जीतने के बाद लिया गया नमूना पॉज़िटिव आया; उस रेस का समय सार्वजनिक नहीं है। - 2019 टोक्यो मैराथन ख़िताब और मेजर्स में तीन दूसरे स्थान इस फ़ैसले से नहीं मिटे। - बत्तीस वर्ष की अगा की वापसी अड़तीस की उम्र में होगी, जिससे शीर्ष स्तर का करियर व्यवहार में समाप्त हो जाता है। **स्रोत**: एथलेटिक्स इंटीग्रिटी यूनिट का बयान, गुरुवार को जारी (बयान की पूर्ण तारीख़ और रेस का वर्ष स्रोत में स्पष्ट नहीं)। **संबंधित प्रश्न-उत्तर**: - प्रश्न: रूटी अगा को छह साल का प्रतिबंध क्यों मिला? उत्तर: दो साल पदार्थ की उपस्थिति और चार साल फर्ज़ी पर्चे से छेड़छाड़ के लिए, जिसे AIU ने दस सितंबर से प्रभावी किया। - प्रश्न: क्या 2019 टोक्यो मैराथन ख़िताब रद्द हुआ? उत्तर: नहीं, प्रतिबंध मार्च की रेस से जुड़ा है और स्रोत में पुराने नतीजे रद्द होने का उल्लेख नहीं है। - प्रश्न: क्या ग्लुकोकोर्टिकॉइड प्रतियोगिता से बाहर जायज़ है? उत्तर: हाँ, वर्ग S9 केवल इन-कॉम्पिटिशन प्रतिबंधित है, इसलिए रूट और टाइमिंग निर्णायक होते हैं।
Let me start where the room went quiet. On Thursday the Athletics Integrity Unit issued its statement, and the thing every road-race report leads with was missing: a time. No finishing mark for the half marathon she won in China in March, no splits, no field strength. What the statement carried was a date and an arithmetic — six years, running from 10 September.
Nine years of watching this sport has taught me that the event always gets left at the back of a disciplinary ruling. What is new here is how far back it went. The question has changed. I no longer want to know how fast she ran. I want to know who put the needle in her knee, and who wrote the paper for it.
Ruti Aga is an Ethiopian marathoner, 32 years old. Her name is familiar even to people who do not read a scoreboard on Sundays: she won the 2026 Tokyo Marathon, and she has three second-place finishes at World Marathon Majors. That record still stands, and no sanction erases it automatically unless the investigation reaches backwards — and no such scope is stated in the source. In March she won a half marathon in China. A sample taken there came back positive. The mark from that race appears nowhere in the release, so any sentence I write about her form would be invention. What can be written is that the race had in-competition testing, because otherwise there is no AIU case at all.
According to the statement, she cited a knee injury and said methylprednisolone was given as treatment. The clinic on the prescription did not exist. The person who wrote it was a family member with no medical registration, who claimed to have used an old prescription pad from a former workplace — and that workplace disowned the claim. Three separate verifications, three separate failures. Those failures built the sanction everyone is now discussing. Two years for presence, four for tampering, six in total. The tampering charge rested on the document and on statements made in interview.
This is where the technical detail sits, and it is the detail that put the case in the wrong headline. Methylprednisolone is not a steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and that class is prohibited in-competition only — by injection, oral or rectal route. Anabolic steroids sit in class S1 and are banned at all times. The distinction is not decorative; it is the legal hinge of the whole file. A glucocorticoid injected into an inflamed knee weeks out from a race is ordinary sports medicine and entirely legal out of competition. It becomes a violation when residues are present in a sample taken in competition. A road race's testing window opens at 23:59 the night before the race, which is why an injection given days earlier can be caught.
Which means a legitimate defence existed. Real medical records, the injection date, the route and the dose — those three could have carried the presence charge to the no-fault or no-significant-fault end, where the outcome is a reprimand or a much shorter period. The opposite happened: the defence was manufactured on paper, and the manufacturing destroyed it. That also answers the question asked in every doping case — did the punishment come from the substance or from the conduct? Here the answer is written in two parts.
Open the arithmetic. Two years for presence fits the pattern of a Specified Substance where intent cannot be proven. Four years for tampering is the Code's standard sanction. The sum is six, and the sum is itself information: had the panel found any solid no-fault basis, the presence limb would have shrunk. It did not shrink. Backdating to 10 September is not a discount either — provisional suspension time counts against the ban, so the athlete gains nothing in real terms. That is procedure, not leniency.
I read this beat through payroll rather than podiums. In India that payroll is a Railways posting, a Services team place, a state police job — the contract that pays next month's rent. In Ethiopia's road-running economy the payroll does not appear on a salary slip, because it runs on an appearance-fee calendar. The Asian label races between Majors, the Chinese half-marathon circuit most visibly, are the door where the fee is good and the risk looks small. Aga's pattern fit that model: selective Majors, Asian label races in between.
That is where a collision sits, and almost nobody names it. The appearance-fee economy and the testing economy are now meeting in the same races. The circuit that is the athlete's most comfortable income is the AIU's highest-yield hunting ground. The same names are on both sides, the same training camp, the same agent.
In 2026, when the country was shut and the national camp was shut, I made thirty-four calls — a Railways-quota sprinter whose posting had frozen, a heptathlete training on a Lucknow terrace, a coach still answering for the 2026 cases. Those calls changed my first question. I now ask 'who pays your rent' before 'what is your target'. This file adds a third: who signs the paper that puts the needle in your knee? In Aga's file the answer is a family member without registration and a clinic that did not exist. That is not a filing error. It is the portrait of an athlete running without a credentialed team doctor.
A properly managed athlete has two routes: hold or apply for a TUE, or observe the route-specific washout. Neither appears to have happened, and that inference comes from the fact that a real record would have made forgery unnecessary.
On the map of the sport, the effect is easy to state. Ethiopia's women's marathon is deep enough that a 2:18 performer is not automatically selectable; there is a world-record tier above and a production line below. One athlete's removal is invisible in selection arithmetic. Reading this as another Ethiopian talent lost misreads it. The case belongs to the governance vacuum that travels with that depth — an elite talent pipeline paired with an almost absent medical-paperwork pipeline.
The age maths is just as plain. Six years at 32 means a return at 38, in front of a selection committee holding a doping record and a queue of 20- and 22-year-olds behind her. In practice this is career-terminal, whatever the paper says.
Now look the other way. The reflex on hearing six years is that anti-doping has got tough. Mine is that the toughness here came from paperwork, not pharmacology. A glucocorticoid has no proven endurance benefit; it reduces swelling, masks pain and buys recovery time. A six-year sanction for a substance that does not build performance landed on the thing that did build: document verification. The enforcement frontier has shifted from detection to paperwork, and this ruling is the evidence.
That is why one headline error will be expensive later. Reports calling methylprednisolone a prohibited steroid placed this case in the anabolic queue. The argument that follows from that placement — heavy-handedness toward African road runners, inequity, double standards — will be standing on a false fact. Class S9 is in-competition only, which is why route and timing decided this file. An argument built on the correct fact will hold. One built on the wrong class dies with the headline.
Keep the asterisk clean on both sides. The 2026 Tokyo title was not stripped. The three Major second places were not erased. The sanction attaches to the March race whose sample was positive; the source does not state the disqualification scope, but standard AIU practice voids that result and its prize money, along with ranking points accrued after it. Both things belong in the same paragraph: the record of a genuinely elite marathoner, and a ruling that closed the part of the record still ahead of her.
Whether Aga is culpable is settled. The live question is who stands next to a 22-year-old in Bekoji or Iten when her knee swells next season. If the answer is the same — a relative, an old pad, nobody who has ever filed a TUE form — the next case is a copy of this file. A TUE desk at agent level, a registered physio and a washout calendar with dates on it cost less than litigation. That advice arrives late for Aga. For the generation behind her it is still on time.
I kept the tape running after the questions ran out, and the only sound left on it was six years. In a sport whose most important number is a finishing time, this athlete's story never began with one. Watch the people standing around the next winner in a Chinese label race, not the scoreboard; the sport lives in their faces, and the paper lives in their pockets.



संबंधित खिलाड़ी
